A Bioequivalence Study of Two Oral Formulations of Linagliptin and Metformin in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of linagliptin/metformin in healthy volunteers. Establishing bioequivalence is clinically relevant as it ensures that the two formulations have similar bioavailability, which is crucial for maintaining therapeutic efficacy and safety. No secondary objectives are specified for this trial.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial population selection criteria include a focus on a vulnerable population, although specific details regarding the total number of participants or additional lifestyle considerations such as diet or physical activity are not provided by the sponsor. The absence of detailed inclusion or exclusion criteria further limits the available information about the participant selection process.

The clinical trial is designed to evaluate the **bioequivalence** of two formulations of linagliptin/metformin in **healthy volunteers**. This study is structured as a Phase 2, randomized, double-blind, controlled trial. The estimated recruitment start date is November 4, 2024, with an anticipated end date of January 27, 2025. The trial will involve a series of study visits, beginning with an inclusion visit where participants will undergo screening to confirm eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to receive one of the two formulations under investigation.

Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and assess the pharmacokinetic parameters of the formulations. These visits are crucial for collecting data on the primary and secondary endpoints, although specific endpoints are not detailed in the available data. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure participant safety and gather comprehensive data for analysis.

The expected duration of participant involvement will align with the overall trial timeline, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with study protocols, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the collection of reliable data while maintaining participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on November 4, 2024, with an estimated completion date of January 27, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 2 trials, focusing on evaluating the treatment's effectiveness within the specified timeframe.